Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Oct;31(5):596-609.
doi: 10.1177/0884533616662996. Epub 2016 Aug 16.

Intravenous Fat Emulsion Formulations for the Adult and Pediatric Patient: Understanding the Differences

Lorenzo Anez-Bustillos  1 , Duy T Dao  1 , Meredith A Baker  1 , Gillian L Fell  1 , Mark Puder  1 , Kathleen M Gura  2
Affiliations
Review

Intravenous Fat Emulsion Formulations for the Adult and Pediatric Patient: Understanding the Differences

Lorenzo Anez-Bustillos et al. Nutr Clin Pract. 2016 Oct.

Abstract

Intravenous fat emulsions (IVFEs) provide essential fatty acids (EFAs) and are a dense source of energy in parenteral nutrition (PN). Parenterally administered lipid was introduced in the 17th century but plagued with side effects. The formulation of IVFEs later on made it a relatively safe component for administration to patients. Many ingredients are common to all IVFEs, yet the oil source(s) and its (their) percentage(s) makes them different from each other. The oil used dictates how IVFEs are metabolized and cleared from the body. The fatty acids (FAs) present in each type of oil provide unique beneficial and detrimental properties. This review provides an overview of IVFEs and discusses factors that would help clinicians choose the optimal product for their patients.

Keywords: fatty acids; intravenous fat emulsions; lipids; parenteral nutrition.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Evolution of fat sources in IVLE and their corresponding changes in inflammatory profile
See this image and copyright information in PMC

References

    1. Carpentier YA, Dupont IE. Advances in intravenous lipid emulsions. [Accessed April 9, 2016];World J Surg. 2000 24(12):1493–1497. http://www.ncbi.nlm.nih.gov/pubmed/11193713. - PubMed
    1. Vinnars E, Hammarqvist F. 25th Arvid Wretlind’s Lecture--Silver anniversary, 25 years with ESPEN, the history of nutrition. Clin Nutr. 2004;23(5):955–962. doi: 10.1016/j.clnu.2004.06.001. - DOI - PubMed
    1. Geyer RP. Parenteral nutrition. [Accessed April 9, 2016];Physiol Rev. 1960 40:150–186. http://www.ncbi.nlm.nih.gov/pubmed/13827710. - PubMed
    1. Wretlind A. Development of fat emulsions. [Accessed April 12, 2016];JPEN J Parenter Enteral Nutr. 1981 5(3):230–235. http://www.ncbi.nlm.nih.gov/pubmed/6788972. - PubMed
    1. Ferezou J, Bach AC. Structure and metabolic fate of triacylglycerol- and phospholipid-rich particles of commercial parenteral fat emulsions. [Accessed June 26, 2016];Nutrition. 1999 15(1):44–50. http://www.ncbi.nlm.nih.gov/pubmed/9918062. - PubMed